Coverage
-
October 28, 2026
The head of the U.S. Patent and Trademark Office has turned down Pogona LLC's argument that Merck's challenge to a patent on selecting a type of bacteria to use in a vaccine against pneumococcal disease was an "abusive" attack on the patent.
2 other articles on this case.
View all »